Plasma miRNA-155 Levels Predict Atrial Fibrillation Recurrence after Cardioversion

Prediction of Atrial Fibrillation Recurrence

  • Xiong Zhang Department of Laboratory, the First People’s Hospital of Xianyang City, Xianyang, Shaanxi Province, China
  • Xiao-ping Xiao Department of Laboratory, the Eighth Hospital of Xi’an City, Xi’an, Shaanxi Province, China
  • Xu-ai Ren Department of Cardiology, the First People’s Hospital of Xianyang, Xianyang, Shaanxi Province, China
  • Tao Cui Department of Cardiology, the First People’s Hospital of Xianyang, Xianyang, Shaanxi Province, China


Background: MicroRNAs (miRNAs) are widely involved in the regulation of physiological processes, such as cell proliferation, differentiation, apoptosis, angiogenesis, and lipid metabolism. They might be associated with the pathological process of atrial fibrillation (AF). The purpose of our study is to investigate whether plasma miRNA-155 levels have a relationship with AF recurrence.

Methods: A total of 110 patients with AF were studied, all with successful cardioversion. We measured the expression of plasma miRNA-155 in the recurrent group (n = 30) and in the nonrecurrent group (n = 80) by quantitative reverse transcription–polymerase chain reaction (qRT-PCR). In addition, the serumal levels of B-type natriuretic peptide (BNP), total cholesterol (TC), and fasting blood glucose (FBG) in the groups were determined by using an automatic biochemical analyzer; and an immunoenzymatic method was applied to determine the serumal levels of tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), and interleukin-6 (IL-6). The left atrial diameter (LAD) and left ventricular ejection fraction (EF) of all patients were measured by using echocardiography.

Results: Our RT-PCR analysis found that miRNA-155 was significantly upregulated in the recurrent group compared with the nonrecurrent group. These increases of LAD and the levels of BNP, TNF-α, CRP, and IL-6 in the recurrent group were also revealed to be relative to those in the nonrecurrent group. There were no differences in the levels of TC and FBG, as well as in EF, between the groups. Moreover, miRNA-155 expression was observed to correlate positively with these outcomes of LAD, BNP, TNF-α, CRP, IL-6, and LAD. A diagnostic significance of predicting AF recurrence for plasma miRNA-155 was elucidated via ROC curve analysis.

Conclusions: Our findings revealed that plasma miRNA-155 can present an ability to calculate AF recurrence after cardioversion.


imé-Sempé C, Folliguet T, Rücker-Martin C, et al. 1999. Myocardial cell death in fibrillating and dilated human right atria. J Am Coll Cardiol 34:1577-86.

Allessie M, Ausma J, Schotten U. 2002. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 54:230-46.

Ausma J, Wijffels M, Thoné F, Wouters L, Allessie M, Borgers M. 1997. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 96:3157-63.

Aviles RJ, Martin DO, Apperson-Hansen C, et al. 2003. Inflammation as a risk factor for atrial fibrillation. Circulation 108:3006-10.

Blanco RR, Austin H, Vest RN 3rd, et al. 2012. Angiotensin receptor type 1 single nucleotide polymorphism 1166A/C is associated with malignant arrhythmias and altered circulating miR-155 levels in patients with chronic heart failure. J Card Fail 18:717-23.

Cai L, Yin Y, Ling Z, et al. 2013. Predictors of late recurrence of atrial fibrillation after catheter ablation. Int J Cardiol 164:82-7.

Casaclang-Verzosa G, Gersh BJ, Tsang TS. 2008. Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol 51:1-11.

Chang SL, Chen YC, Chen YJ, et al. 2007. Mechanoelectrical feedback regulates the arrhythmogenic activity of pulmonary veins. Heart 93:82-8.

Chugh SS, Havmoeller R, Narayanan K, et al. 2014. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 129:837-47.

den Uijl DW, Delgado V, Bertini M, et al. 2011. Impact of left atrial fibrosis and left atrial size on the outcome of catheter ablation for atrial fibrillation. Heart 97:1847-51.

Fichtlscherer S, De Rosa S, Fox H, et al. 2010. Circulating microRNAs in patients with coronary artery disease. Circ Res 107:677-84.

Filipowicz W, Bhattacharyya SN, Sonenberg N. 2008. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9:102-14.

Genovesi S, Rossi E, Gallieni M, et al. 2015. Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation. Nephrol Dial Transplant 30:491-8.

Hou J, Wang P, Lin L, et al. 2009. MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J Immunol 183:2150-8.

January CT, Wann LS, Alpert JS, et al. 2014. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 130:2071-104.

Jiang S, Zhang HW, Lu MH, et al. 2010. MicroRNA-155 functions as an oncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 70:3119-27.

Kannel WB, Benjamin EJ. 2009. Current perceptions of the epidemiology of atrial fibrillation. Cardiol Clin 27:13-24, vii.

Kannel WB, Wolf PA, Benjamin EJ, Levy D. 1998. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 82(7 suppl 1):2N-9N.

Katsanos S, Mavrogenis AF, Kafkas N, et al. 2017. Cardiac biomarkers predict 1-year mortality in elderly patients undergoing hip fracture surgery. Orthopedics 40:e417-24.

Kirchhof P, Benussi S, Kotecha D, et al. 2016. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893-962.

Li D, Fareh S, Leung TK, Nattel S. 1999. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 100:87-95.

Lu ZJ, Wu JJ, Jiang WL, et al. 2017. MicroRNA-155 promotes the pathogenesis of experimental colitis by repressing SHIP-1 expression. World J Gastroenterol 23:976-85.

Marchese P, Bursi F, Delle Donne G, et al. 2011. Indexed left atrial volume predicts the recurrence of non-valvular atrial fibrillation after successful cardioversion. Eur J Echocardiogr 12:214-21.

Marfella R, Sasso FC, Siniscalchi M, et al. 2013. Brief episodes of silent atrial fibrillation predict clinical vascular brain disease in type 2 diabetic patients. J Am Coll Cardiol 62:525-30.

Marrouche NF, Wilber D, Hindricks G, et al. 2014. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA 311:498-506.

Mitrić G, Udy A, Bandeshe H, Clement P, Boots R. 2016. Variable use of amiodarone is associated with a greater risk of recurrence of atrial fibrillation in the critically ill. Crit Care 20:90.

Naccarelli GV, Varker H, Lin J, Schulman KL. 2009. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 104:1534-9.

Nattel S, Harada M. 2014. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol 63:2335-45.

O’Connell RM, Kahn D, Gibson WS, et al. 2010. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 33:607-19.

O’Connell RM, Rao DS, Baltimore D. 2012. microRNA regulation of inflammatory responses. Annu Rev Immunol 30:295-312.

O’Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. 2007. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA 104:1604-9.

Pison L, Tilz R, Jalife J, Haïssaguerre M. 2016. Pulmonary vein triggers, focal sources, rotors and atrial cardiomyopathy: implications for the choice of the most effective ablation therapy. J Intern Med 279:449-56.

Rebane A, Akdis CA. 2013. MicroRNAs: essential players in the regulation of inflammation. J Allergy Clin Immunol 132:15-26.

Rücker-Martin C, Pecker F, Godreau D, Hatem SN. 2002. Dedifferentiation of atrial myocytes during atrial fibrillation: role of fibroblast proliferation in vitro. Cardiovasc Res 55:38-52.

Sardu C, Santamaria M, Paolisso G, Marfella R. 2015. microRNA expression changes after atrial fibrillation catheter ablation. Pharmacogenomics 16:1863-77.

Sardu C, Santulli G, Santamaria M, et al. 2017. Effects of alpha lipoic acid on multiple cytokines and biomarkers and recurrence of atrial fibrillation within 1 year of catheter ablation. Am J Cardiol 119:1382-6.

Sinner MF, Stepas KA, Moser CB, et al. 2014. B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies. Europace 16:1426-33.

van Berkel TJ, Out R, Hoekstra M, Kuiper J, Biessen E, van Eck M. 2005. Scavenger receptors: friend or foe in atherosclerosis? Curr Opin Lipidol 16:525-35.

Vaziri SM, Larson MG, Lauer MS, Benjamin EJ, Levy D. 1995. Influence of blood pressure on left atrial size. The Framingham Heart Study. Hypertension 25:1155-60.

Verheule S, Tuyls E, van Hunnik A, Kuiper M, Schotten U, Allessie M. 2010. Fibrillatory conduction in the atrial free walls of goats in persistent and permanent atrial fibrillation. Circ Arrhythm Electrophysiol 3:590-9.

Wang J, Song S, Xie C, et al. 2015. MicroRNA profiling in the left atrium in patients with non-valvular paroxysmal atrial fibrillation. BMC Cardiovasc Disord 15:97.

Xu J, Cui G, Esmailian F, et al. 2004. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 109:363-8.